Literature DB >> 16534790

Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma.

T Trahair1, L Andrews, R J Cohn.   

Abstract

A contemporaneous presentation of a second breast cancer in a mother and an extremity rhabdomyosarcoma (RMS) in her daughter led to the diagnosis of the Li Fraumeni syndrome (LFS). Although the association between LFS and RMS in young patients is well recognised 1 there are no guidelines as to how this knowledge should influence the optimal management of these patients. After reviewing the literature about the natural history of the LFS 2, the incidence of second malignancy (SMN) in RMS survivors 3-6 and the management of extremity RMS 7-9, we are concerned that contemporary RMS treatment, combining non-mutilating surgery with chemoradiotherapy, may be associated with an excessive SMN risk in LFS patients with advanced RMS. We question whether treatment should be individualised and, where possible and acceptable to the family, measures such as amputation should be the considered to attain local control for LFS patients with RMS as this will avoid the need for local radiotherapy without compromising long-term function and quality of life 10. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16534790     DOI: 10.1002/pbc.20795

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53.

Authors:  Alessandra Ferrarini; Agnes Auteri-Kaczmarek; Alessia Pica; Nemya Boesch; Karl Heinimann; Stephan C Schäfer; Sara Vesnaver-Megalo; Viviane Cina; Jacques S Beckmann; Christian Monnerat
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations.

Authors:  Louis P Dehner; Jason A Jarzembowski; D Ashley Hill
Journal:  Mod Pathol       Date:  2011-12-09       Impact factor: 7.842

3.  Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.

Authors:  S Ognjanovic; S E Carozza; E J Chow; E E Fox; S Horel; C C McLaughlin; B A Mueller; S Puumala; P Reynolds; J Von Behren; L Spector
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

4.  Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.

Authors:  Francesca Megiorni; Samantha Cialfi; Heather P McDowell; Armando Felsani; Simona Camero; Alessandro Guffanti; Barry Pizer; Anna Clerico; Alessandra De Grazia; Antonio Pizzuti; Anna Moles; Carlo Dominici
Journal:  BMC Cancer       Date:  2014-11-25       Impact factor: 4.430

5.  Molecular profile of tongue cancer in an 18-year-old female patient with no recognizable risk factor.

Authors:  Melvin A Ambele; Michael S Pepper; Marlene B van Heerden; Willie F P van Heerden
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-04-23

Review 6.  MiRNAs as Players in Rhabdomyosarcoma Development.

Authors:  Patrizia Gasparini; Andrea Ferrari; Michela Casanova; Francesca Limido; Maura Massimino; Gabriella Sozzi; Orazio Fortunato
Journal:  Int J Mol Sci       Date:  2019-11-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.